The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: Correlation with morphological changes on CT

Molecular Imaging and Biology

Volumn 12, Issue 1, 2010, Pages 98-107

  Beheshti, Mohsen ^a   Vali, Reza ^a   Waldenberger, Peter ^b   Fitz, Friedrich ^a   Nader, Michael ^a   Hammer, Josef ^b   Loidl, Wolfgang ^b   Pirich, Christian ^c   Fogelman, Ignac ^d   Langsteger, Werner ^a  

^a St Vincent's Hospital Nuclear Medicine and Endocrinology   (Austria)

^b St Vincent's Hospital   (Austria)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Bone metastases; F 18 fluor choline PET CT; Hounsfield unit; Prostate cancer

Indexed keywords

CHOLINE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; FOLLOW UP; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; RADIOCHEMISTRY; SENSITIVITY AND SPECIFICITY;

AGED; BONE NEOPLASMS; CHOLINE; DISEASE PROGRESSION; FLUORINE RADIOISOTOPES; HORMONES; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77149155343     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-009-0239-7     Document Type: Article

References (42)

1. A Jemal RC Tiwari T Murray, et al. 2004 Cancer statistics, 2004 CA Cancer J Clin 54 1 8 29 10.3322/canjclin.54.1.8 14974761
2. M Han AW Partin M Zahurak S Piantadosi JI Epstein PC Walsh 2003 Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer J Urol 169 2 517 523 10.1016/S0022-5347(05)63946-8 12544300 (Pubitemid 36132976)
3. H Hricak H Schoder D Pucar, et al. 2003 Advances in imaging in the postoperative patient with a rising prostate-specific antigen level Semin Oncol 30 5 616 634 10.1016/S0093-7754(03)00359-2 14571410 (Pubitemid 37296787)
4. H Schoder SM Larson 2004 Positron emission tomography for prostate, bladder, and renal cancer Semin Nucl Med 34 4 274 292 10.1053/j.semnuclmed.2004. 06.004 15493005 (Pubitemid 39365998)
5. E Even-Sapir U Metser E Mishani G Lievshitz H Lerman I Leibovitch 2006 The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT J Nucl Med 47 2 287 297 16455635
6. S Abuzallouf I Dayes H Lukka 2004 Baseline staging of newly diagnosed prostate cancer: a summary of the literature J Urol 171 6 Pt 1 2122 2127 10.1097/01.ju.0000123981.03084.06 15126770 (Pubitemid 38625418)
7. I Fogelman G Cook O Israel H Van der Wall 2005 Positron emission tomography and bone metastases Semin Nucl Med 35 2 135 142 10.1053/j.semnuclmed. 2004.11.005 15765376 (Pubitemid 40568746)
8. N Lee R Fawaaz CA Olsson, et al. 2000 Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients Int J Radiat Oncol Biol Phys 48 5 1443 1446 1:STN:280: DC%2BD3M%2FnvVWitg%3D%3D 11121646
9. LF Wymenga JH Boomsma K Groenier DA Piers HJ Mensink 2001 Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase BJU Int 88 3 226 230 10.1046/j.1464-410x.2001. 02275.x 1:STN:280:DC%2BD3Mvkt1Kiug%3D%3D 11488734 (Pubitemid 32863042)
10. BK Yap R Choo G Deboer L Klotz C Danjoux G Morton 2003 Are serial bone scans useful for the follow-up of clinically localized, low to intermediate grade prostate cancer managed with watchful observation alone? BJU Int 91 7 613 617 10.1046/j.1464-410X.2003.04169.x 1:STN:280:DC%2BD3s7otV2ktA%3D%3D 12699470 (Pubitemid 36583729)
11. P Gomez M Manoharan SS Kim MS Soloway 2004 Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated? BJU Int 94 3 299 302 10.1111/j.1464-410X.2004.04927.x 15291855 (Pubitemid 39120167)
12. J Rigaud R Tiguert L Le Normand, et al. 2002 Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy J Urol 168 4 Pt 1 1423 1426 12352409
13. P Sabbatini SM Larson A Kremer, et al. 1999 Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer J Clin Oncol 17 3 948 957 1:STN:280:DyaK1M7mvVyntQ%3D%3D 10071289
14. AF Jacobson I Fogelman 1998 Bone scanning in clinical oncology: does it have a future? Eur J Nucl Med 25 9 1219 1223 10.1007/s002590050287 1:STN:280:DyaK1czptFOjuw%3D%3D 9724368 (Pubitemid 28446045)
15. H Schirrmeister G Glatting J Hetzel, et al. 2001 Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18) F-labeled NaF PET in newly diagnosed lung cancer J Nucl Med 42 12 1800 1804 1:STN:280: DC%2BD38%2FgtlOgsg%3D%3D 11752076
16. H Schirrmeister A Guhlmann K Elsner, et al. 1999 Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET J Nucl Med 40 10 1623 1629 1:STN:280:DyaK1MvkvFSisw%3D%3D 10520701
17. PJ Effert R Bares S Handt JM Wolff U Bull G Jakse 1996 Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose J Urol 155 3 994 998 10.1016/S0022-5347(01) 66366-3 1:STN:280:DyaK287msVKnug%3D%3D 8583625 (Pubitemid 26052696)
18. R Heicappell V Muller-Mattheis M Reinhardt, et al. 1999 Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18) F]-2-deoxy-D-glucose Eur Urol 36 6 582 587 10.1159/000020052 1:STN:280:DC%2BD3c%2Fis1SmtA%3D%3D 10559612 (Pubitemid 29516289)
19. C Hofer C Laubenbacher T Block J Breul R Hartung M Schwaiger 1999 Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy Eur Urol 36 1 31 35 10.1159/000019923 1:STN:280:DyaK1M3psVOiuw%3D%3D 10364652 (Pubitemid 29265277)
20. IJ Liu MB Zafar YH Lai GM Segall MK Terris 2001 Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer Urology 57 1 108 111 10.1016/S0090-4295(00)00896- 7 1:STN:280:DC%2BD3M3is1emtQ%3D%3D 11164153 (Pubitemid 32065829)
21. MJ Morris T Akhurst I Osman, et al. 2002 Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer Urology 59 6 913 918 10.1016/S0090-4295(02)01509-1 12031380 (Pubitemid 34522186)
22. PD Shreve HB Grossman MD Gross RL Wahl 1996 Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose Radiology 199 3 751 756 1:STN:280:DyaK283itVGgug%3D%3D 8638000
23. W Langsteger M Heinisch I Fogelman 2006 The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast Semin Nucl Med 36 1 73 92 10.1053/j.semnuclmed. 2005.09.002 16356797 (Pubitemid 41782168)
24. M Cimitan R Bortolus S Morassut, et al. 2006 [(18) F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients Eur J Nucl Med Mol Imaging 33 12 1387 1398 10.1007/s00259-006-0150-2 16865395 (Pubitemid 44885404)
25. SN Reske NM Blumstein B Neumaier, et al. 2006 Imaging prostate cancer with 11C-choline PET/CT J Nucl Med 47 8 1249 1254 1:CAS:528:DC%2BD28XptVWqu7w%3D 16883001
26. T Hara N Kosaka H Kishi 1998 PET imaging of prostate cancer using carbon-11-choline J Nucl Med 39 6 990 995 1:CAS:528:DyaK1cXktV2itrg%3D 9627331
27. SA Kwee H Wei I Sesterhenn D Yun MN Coel 2006 Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET J Nucl Med 47 2 262 269 16455632
28. DT Schmid H John R Zweifel, et al. 2005 Fluorocholine PET/CT in patients with prostate cancer: initial experience Radiology 235 2 623 628 10.1148/radiol.2352040494 15858102 (Pubitemid 40571106)
29. D Vassiliev R Krasikova O Kutznetsova O Federova M Nader 2003 Simple HPLC method for the detection of N, N-dimethylaminoethanol in the preparation of [N-methyl-11C] choline Eur J Nucl Med Mol Imaging 30 342P
30. C Lin E Itti C Haioun, et al. 2007 Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis J Nucl Med 48 10 1626 1632 10.2967/jnumed.107.042093 17873129 (Pubitemid 47572710)
31. WA Hallett PK Marsden BF Cronin MJ O'Doherty 2001 Effect of corrections for blood glucose and body size on [18F]FDG PET standardised uptake values in lung cancer Eur J Nucl Med 28 7 919 922 10.1007/s002590100561 1:CAS:528:DC%2BD3MXkvVWltbo%3D 11504091 (Pubitemid 32662557)
32. E Even-Sapir E Mishani G Flusser U Metser 2007 18F-Fluoride positron emission tomography and positron emission tomography/computed tomography Semin Nucl Med 37 6 462 469 10.1053/j.semnuclmed.2007.07.002 17920353 (Pubitemid 47505220)
33. E Even-Sapir U Metser G Flusser, et al. 2004 Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT J Nucl Med 45 2 272 278 14960647
34. H Schirrmeister A Guhlmann J Kotzerke, et al. 1999 Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography J Clin Oncol 17 8 2381 2389 1:STN:280:DC%2BD3c%2FjtVShuw%3D%3D 10561300
35. SD Yeh M Imbriaco SM Larson, et al. 1996 Detection of bony metastases of androgen-independent prostate cancer by PET-FDG Nucl Med Biol 23 6 693 697 10.1016/0969-8051(96)00044-3 1:STN:280:DyaK2s%2FpsFekuw%3D%3D 8940712 (Pubitemid 26342473)
36. GJ Cook S Houston R Rubens MN Maisey I Fogelman 1998 Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions J Clin Oncol 16 10 3375 3379 1:STN:280:DyaK1cvltV2qtw%3D%3D 9779715
37. MJ Morris T Akhurst SM Larson, et al. 2005 Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy Clin Cancer Res 11 9 3210 3216 10.1158/1078-0432.CCR-04-2034 1:CAS:528:DC%2BD2MXjslOqsb4%3D 15867215 (Pubitemid 40627867)
38. W Langsteger M Beheshti M Nader, et al. 2006 Evaluation of lymph node and bone metastases with Fluor Choline (FCH) PET-CT in the follow up of prostate cancer patients Eur J Nucl Med Mol Imaging 33 Suppl 2 209
39. CS Galasko 1986 Skeletal metastases Clin Orthop Relat Res 210 18 30 3757360
40. AC Clavo RS Brown RL Wahl 1995 Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia J Nucl Med 36 9 1625 1632 1:CAS:528:DyaK2MXot1Gmsrg%3D 7658223
41. RL Vessella E Corey 2006 Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis Clin Cancer Res 12 20 Pt 2 6285 6290 10.1158/1078-0432.CCR-06-0813 (Pubitemid 44703804)
42. M Goya G Ishii S Miyamoto, et al. 2006 Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer The Prostate 66 15 1573 1584 10.1002/pros.20375 1:CAS:528:DC%2BD28Xht1Oktb7I 16927388 (Pubitemid 44646349)